Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
The current price of HOWL is $0.40 USD — it has increased by +6.47% in the past 24 hours. Watch Werewolf Therapeutics stock price performance more closely on the chart.
What is Werewolf Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Werewolf Therapeutics stocks are traded under the ticker HOWL.
Is Werewolf Therapeutics stock price growing?▼
HOWL stock has risen by +18.39% compared to the previous week, the month change is a +5.77% rise, over the last year Werewolf Therapeutics has showed a -66.13% decrease.
What is Werewolf Therapeutics market cap?▼
Today Werewolf Therapeutics has the market capitalization of 19.58M
When is the next Werewolf Therapeutics earnings date?▼
Werewolf Therapeutics is going to release the next earnings report on August 06, 2026.
What were Werewolf Therapeutics earnings last quarter?▼
HOWL earnings for the last quarter are -0.28 USD per share, whereas the estimation was -0.27 USD resulting in a -3.7% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Werewolf Therapeutics revenue for the last year?▼
Werewolf Therapeutics revenue for the last year amounts to 0 USD.
What is Werewolf Therapeutics net income for the last year?▼
HOWL net income for the last year is -60.82M USD.
How many employees does Werewolf Therapeutics have?▼
As of July 12, 2026, the company has 46 employees.
In which sector is Werewolf Therapeutics located?▼
Werewolf Therapeutics operates in the Health & Wellness sector.
When did Werewolf Therapeutics complete a stock split?▼
Werewolf Therapeutics has not had any recent stock splits.
Where is Werewolf Therapeutics headquartered?▼
Werewolf Therapeutics is headquartered in Watertown, United States.